Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 3/20 | 0.42 |
| ▸ | ACVRL1 | P37023 | 7/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 7/20 | 0.38 |
| ▸ | BMPR1A | P36894 | 6/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.37 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.37 |
| ▸ | CYP3A43 | Q9HB55 | 2/20 | 0.37 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16610735 | 0.99 | KDM5A (0.42) | KDM5AACVRL1ACVR1BMPR1ACYP1A2 | |
| SCHEMBL16611405 | 0.90 | BMPR1A (0.38) | KDM5AACVRL1ACVR1BMPR1AXDH | |
| SCHEMBL16611071 | 0.86 | JAK1 (0.35) | KDM5AACVRL1ACVR1BMPR1AXDH | |
| SCHEMBL16610767 | 0.84 | MTOR (0.36) | KDM5AXDHJAK2 | |
| SCHEMBL16611490 | 0.84 | KDM5A (0.42) | KDM5AXDHJAK2KDM5B | |
| SCHEMBL16611308 | 0.83 | ALK (0.35) | ACVRL1ACVR1BMPR1AXDHJAK2 | |
| SCHEMBL16610802 | 0.83 | SRC (0.41) | KDM5ACYP1A2CYP3A4CYP2C19XDH | |
| SCHEMBL16611598 | 0.82 | XDH (0.38) | KDM5AXDH | |
| SCHEMBL16611028 | 0.79 | LRRK2 (0.42) | XDH | |
| SCHEMBL16610742 | 0.78 | XDH (0.37) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | KDM5A 132/4885ACVRL1 961/4885ACVR1 663/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | KDM5A 132/4885ACVRL1 961/4885ACVR1 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.